14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BNBX vs PACB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, BNB Plus Corp. (BNBX) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.88 (N/M Forward P/E, -333.0% operating margin).
Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. BNBX 37.7/100 SELL), BNBX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-636.4% vs. -333.0% operating margin) and revenue trajectory (+34.3% vs. +5.5% YoY).
Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BNBX vs PACB Key Questions & Quantitative Answers
As of Nov 16, 2026, BNB Plus Corp. (BNBX) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.88 (N/M Forward P/E, -333.0% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. BNBX 37.7/100 SELL), BNBX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-636.4% vs. -333.0% operating margin) and revenue trajectory (+34.3% vs. +5.5% YoY). Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PACB leads the Growth & Scale pillar: BNBX posts +34.3% YoY revenue growth and +0.0% YoY earnings growth on $2.1M TTM revenue (46.8% gross margin, -636.4% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BNBX cumulative revenue shifted +0.0% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, BNBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.
BNBX screens cheaper on headline valuation multiples. BNBX trades at N/M Forward P/E, N/M Trailing P/E, 1.27x PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BNBX (-306.8% ROE) versus PACB (-929.3% ROE) capital efficiency.
In options market volatility and institutional positioning, BNBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 227% Vol realized risk). By comparison, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 110% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.